We'd like your feedback
Your feedback is important to us. It will help us improve the quality of the study information on this site. Please answer both questions.
Contact the study team using the details below to take part. If there are no contact details below please ask your doctor in the first instance.
Dermatitis and eczema
This information is provided directly by researchers, and we recognise that it isn't always easy to understand. We are working with researchers to improve the accessibility of this information. In some summaries, you may come across links to external websites. These websites will have more information to help you better understand the study.
This is a single centre randomised, placebo-controlled phase 2 study in which children age 4 to 16 years with moderate to severe, longstanding allergic eczema will be enrolled.
Following a 4 to 6 week period on standardised treatment (run-in period, to ensure everyone starts with the same treatment approach), participants will be randomised to an active or dummy temperature-controlled laminar airflow (TLA) device, which has been shown to markedly reduce exposure to particles which can cause allergic reactions when being inhaled (inhaled allergens) and other particles which are in the air we breathe in. This has been shown to be an effective treatment of atopic asthma.
The participants will undergo a 12-week treatment period. The device will then be removed and a final follow-up visit occurs at 16 weeks.
Start dates may differ between countries and research sites. The research team are responsible for keeping the information up-to-date.
The recruitment start and end dates are as follows:
Interventional type: Device;
You can take part if:
You may not be able to take part if:
Very severe atopic dermatitis Use of systemic immunosuppression (such as cyclosporine, methotrexate, azathioprine, oral steroids) or UV therapy or extracorporeal photopheresis within four weeks prior to the screening visit. Received therapeutic monoclonal antibodies (such as Omalizumab or Dupilumab) within six months prior to the screening visit On-going or planned desensitisation / immunotherapy during the study Infections requiring systemic antimicrobial treatment within four weeks prior to the screening visit Introduction of special dietary restriction (for eczema treatment) within three months prior to screening visit Severe asthma > = Step 4 and/or > = 1 course of systemic oral steroids for asthma in the three months prior to screening visit Significant underlying chronic medical condition (chronic other skin disease, inflammatory bowel disease, immunodeficiency's, other uncontrolled systemic disease, cancer) Planned time away from home (=unable to use TLA) exceeding 2 days/week
Below are the locations for where you can take part in the trial. Please note that not all sites may be open.
The study is sponsored by Imperial College of Science, Technology and Medicine and funded by J P MOULTON CHARITABLE FOUNDATION .
Your feedback is important to us. It will help us improve the quality of the study information on this site. Please answer both questions.
Read full details
for Trial ID: CPMS 41107
You can print or share the study information with your GP/healthcare provider or contact the research team directly.
